Tocilizumab is an anti-IL-6 receptor (IL-6R) antibody that targets IL-6 signaling, while etanercept is a conjoined structure of the p75 region of TNF receptor 2 (TNFR2) and Fc portion of immunoglobulin that targets TNFα to treat patients with RA. The gene discussed is TNF; the disease is rheumatoid arthritis.